Tislelizumab

Generic Name: Tislelizumab

Brand Names: Tevimbra, Tizveni

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1858168-59-8

Unique Ingredient Identifier: 0KVO411B3N

Background: Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).

Indication: ⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。

⑵用于治疗局部晚期或转移性尿路上皮癌。

⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。

⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。

⑸用于治疗晚期恶性实体瘤

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma

Phase 2

Conditions: Primary Central Nervous System Lymphoma

Interventions: Drug: orelabrutinib
Drug: Sintilimab
Drug: Tislelizumab

First Posted Date: 2021-05-24

Last Posted Date: 2021-05-24

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 32

Registration Number: NCT04899427

Locations: 🇨🇳
Wei Zhang, Beijing, Beijing, China

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Phase 3

Terminated

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Tislelizumab
Drug: Durvalumab
Drug: Ociperlimab
Drug: Chemotherapy
Radiation: Radiotherapy

First Posted Date: 2021-04-29

Last Posted Date: 2024-10-31

Lead Sponsor: BeiGene

Target Recruit Count: 63

Registration Number: NCT04866017

Locations: 🇺🇸
XCancer/Centeral Care Center, Bolivar, Missouri, United States
🇦🇺
Southern Medical Day Care Centre, Wollongong, New South Wales, Australia
🇦🇺
Townsville Hospital, Douglas, Queensland, Australia

and more 29 locations

Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer

Phase 2

Conditions: Non-small Cell Lung Cancer
Stage III

Interventions: Drug: tislelizumab

First Posted Date: 2021-04-29

Last Posted Date: 2021-04-29

Lead Sponsor: West China Hospital

Target Recruit Count: 33

Registration Number: NCT04865705

Locations: 🇨🇳
University, Chengdu, Sichuan, China

Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Phase 2

Conditions: Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Interventions: Drug: Tislelizumab
Radiation: IMRT

First Posted Date: 2021-04-20

Last Posted Date: 2021-04-20

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 30

Registration Number: NCT04850157

Locations: 🇨🇳
Zhongshan hospital, Fudan University, Shanghai, China

A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT

Phase 2

Recruiting

Conditions: Chemotherapy Effect
Hodgkin Lymphoma

First Posted Date: 2021-04-13

Last Posted Date: 2021-04-13

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 30

Registration Number: NCT04843267

Locations: 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

Phase 2

Recruiting

Conditions: Classical Hodgkin Lymphoma

Interventions: Drug: Tislelizumab

First Posted Date: 2021-04-08

Last Posted Date: 2024-07-26

Lead Sponsor: University of Cologne

Target Recruit Count: 120

Registration Number: NCT04837859

Locations: 🇩🇪
1st Department of Medicine, Cologne University Hospital, Cologne, Germany

A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study

Phase 2

Conditions: Head and Neck Cancer
Radiation
PD-1

First Posted Date: 2021-03-24

Last Posted Date: 2021-03-24

Lead Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Target Recruit Count: 38

Registration Number: NCT04814069

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors

Phase 2

Recruiting

Conditions: MSI-H Colorectal Cancer
Melanoma
Anal Carcinoma
Mesothelioma
Triple Negative Breast Cancer
Lung Adenocarcinoma
Cholangiocarcinoma
Cervical Carcinoma
Kidney Clear Cell Carcinoma
Stomach Adenocarcinoma

Interventions: Drug: Spartalizumab
Drug: Tislelizumab

First Posted Date: 2021-03-17

Last Posted Date: 2023-07-07

Lead Sponsor: SOLTI Breast Cancer Research Group

Target Recruit Count: 184

Registration Number: NCT04802876

Locations: 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸
Hospital Universitari Sant Joan de Reus, Reus, Tarragona, Spain
🇪🇸
Hospital Virgen del Rocío, Sevilla, Spain

and more 10 locations

A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma

Phase 2

Recruiting

Conditions: Advanced Gastric Cancer

Interventions: Drug: Transcatheter Arterial Chemoembolization
Drug: Tislelizumab

First Posted Date: 2021-03-16

Last Posted Date: 2024-05-23

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 71

Registration Number: NCT04799548

Locations: 🇨🇳
ZhongShan hospital Fudan university, Shanghai, Shanghai, China

Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer

Phase 2

Conditions: Colo-rectal Cancer
Gastric Cancer

Interventions: Drug: Tislelizumab
Drug: Anlotinib

First Posted Date: 2021-03-02

Last Posted Date: 2021-03-04

Lead Sponsor: Peking University

Target Recruit Count: 40

Registration Number: NCT04777162

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy